Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Both the India and GCC entities will be operated by separate dedicated management teams
Subscribe To Our Newsletter & Stay Updated
